May Hill Capital LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,175 shares of the company's stock, valued at approximately $315,000.
Other large investors also recently modified their holdings of the company. Invenio Wealth Partners LLC raised its holdings in Johnson & Johnson by 3.7% during the fourth quarter. Invenio Wealth Partners LLC now owns 3,404 shares of the company's stock worth $492,000 after buying an additional 120 shares during the last quarter. Lokken Investment Group LLC increased its position in shares of Johnson & Johnson by 1.7% during the fourth quarter. Lokken Investment Group LLC now owns 15,199 shares of the company's stock worth $2,198,000 after acquiring an additional 247 shares in the last quarter. Geode Capital Management LLC lifted its position in Johnson & Johnson by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock valued at $8,321,881,000 after acquiring an additional 1,561,036 shares in the last quarter. Nemes Rush Group LLC increased its holdings in Johnson & Johnson by 14.6% during the 4th quarter. Nemes Rush Group LLC now owns 55,954 shares of the company's stock worth $8,092,000 after purchasing an additional 7,114 shares in the last quarter. Finally, StoneX Group Inc. raised its stake in shares of Johnson & Johnson by 40.5% in the fourth quarter. StoneX Group Inc. now owns 42,849 shares of the company's stock worth $6,197,000 after purchasing an additional 12,359 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Johnson & Johnson
In other news, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.
Johnson & Johnson Stock Performance
NYSE:JNJ traded down $12.60 on Tuesday, reaching $153.25. 23,293,291 shares of the company's stock were exchanged, compared to its average volume of 7,720,065. The stock has a fifty day simple moving average of $159.16 and a 200-day simple moving average of $155.99. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a market cap of $369.30 billion, a price-to-earnings ratio of 23.04, a P/E/G ratio of 2.56 and a beta of 0.47.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson's revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.29 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.24%. Johnson & Johnson's dividend payout ratio is currently 74.59%.
Wall Street Analysts Forecast Growth
JNJ has been the topic of several analyst reports. Argus raised Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Royal Bank of Canada reiterated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Stifel Nicolaus dropped their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research report on Thursday, January 23rd. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Finally, Barclays lifted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a research report on Tuesday, January 28th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus target price of $171.33.
Check Out Our Latest Report on Johnson & Johnson
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
